Close Menu

NEW YORK (GenomeWeb) – When the choice is whether to prescribe patients experimental, targeted drugs based on genetic markers driving their tumors, or recommend immunotherapies, doctors are often going with the latter, a recent survey found.

A sampling of more than 100 physicians showed that more than two-thirds preferred prescribing patients a type of immunotherapy, called a checkpoint inhibitor, rather than direct them to an experimental targeted drug based on genomic testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.